Yan Chen

President & CEO Elpis Biopharmaceuticals

Yan brings more than 20 years of expertise in both mRNA display technology and biologic drug discovery in the oncology disease area. She was Biotherapeutics Discovery Head at Juno Therapeutics in Boston and Senior Vice President of Research at X-Body Biosciences which was acquired by Juno in 2015. Previously, she was an investigator and project leader in Oncology Biotherapeutics at Novartis Institutes for Biomedical Research. Earlier in her career, she was a scientist at Phylos and Adnexus playing instrumental roles in establishing the mRNA antibody and protein display technology platforms. Yan was a postdoctoral trainee in Immunology at Tufts Medical School and received her PhD in Tumor Immunology from National University of Singapore. She is the co-inventor of more than 20 antibody technologies and biologic therapeutics patents.

January 26, 2021

12:45 PM Breaking Through with CarT & The Next Generation of Therapies

What will it take to carry the next generation of therapy through to broader cancer indications? Analyze existing clinical data and solution-driven strategies. Explore the landscape for Allo vs Auto approaches, and how to best address the clinical and commercial challenges faced by patient specific therapies. How can industry navigate a very transitional landscape and what is the impact of operating in a rapidly changing environment?